Target Name: ANKUB1
NCBI ID: G389161
Review Report on ANKUB1 Target / Biomarker Content of Review Report on ANKUB1 Target / Biomarker
ANKUB1
Other Name(s): Ankyrin repeat and ubiquitin domain-containing 1 | Ankyrin repeat and ubiquitin domain containing 1, transcript variant 1 | ANKUB_HUMAN | Protein ANKUB1 | ankyrin repeat and ubiquitin domain containing 1 | C3orf16 | Protein ANKUB1 (isoform 1) | ANKUB1 variant 1

ANKUB1: A Potential Drug Target and Biomarker

Ankyrin repeat and ubiquitin domain-containing 1 (ANKUB1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of cell growth, differentiation, and survival, and is involved in a variety of physiological processes, including cell signaling, DNA replication, and stress response. The ANKUB1 gene has an attractive profile for drug targeting due to its unique structure and the involvement of a conserved domain that is involved in protein-protein interactions.

The ANKUB1 gene is located on chromosome 16 and has a length of 214 nucleotides. It consists of a unique open reading frame that is characterized by an N-terminus that is rich in conserved amino acid sequence, a central regions that are highly conserved across different species, and a C-terminus that is rich in conserved amino acids and tail region. The ANKUB1 gene has a specific structure that allows it to interact with various protein partners, including other RNA molecules and proteins.

One of the key features of ANKUB1 is its ability to interact with the protein Ubiquitin. Ubiquitin is a highly conserved protein that is involved in a variety of cellular processes, including protein degradation and regulation of DNA replication. It is characterized by a long coiled region that contains a domain that is involved in protein-protein interactions and a second domain that is involved in protein-DNA interactions. The ANKUB1 gene has been shown to interact with the Ubiquitin protein and this interaction may play a role in the regulation of cellular processes.

Another potential drug target for ANKUB1 is its role in cell signaling. ANKUB1 has been shown to be involved in the regulation of cellular signaling pathways, including the G1/S transition and the G0/G1 transition. It has been shown to play a role in the regulation of cell cycle progression and in the control of cell survival. This suggests that ANKUB1 may be a potential drug target for diseases that are characterized by uncontrolled cell growth or dysfunction.

In addition to its potential drug target properties, ANKUB1 also has potential as a biomarker. The ANKUB1 gene has been shown to be expressed in a variety of tissues and cells, including cancer cells, fetal tissues, and stem cells. This suggests that it may be a useful biomarker for the study of disease and cancer. It is also worth noting that ANKUB1 has been shown to be involved in the regulation of cellular processes that are relevant to a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This suggests that ANKUB1 may be a potential biomarker for a range of diseases.

In conclusion, ANKUB1 is a non-coding RNA molecule that has a unique structure and is involved in a variety of physiological processes. Its conserved domain and its ability to interact with the protein Ubiquitin make it a potential drug target, and its expression in a variety of tissues and cells makes it a potential biomarker. Further research is needed to fully understand the role of ANKUB1 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Ankyrin Repeat And Ubiquitin Domain Containing 1

The "ANKUB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKUB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ANKZF1 | ANLN | Annexin | ANO1 | ANO10 | ANO2 | ANO3 | ANO4 | ANO5 | ANO6 | ANO7 | ANO7L1 | ANO8 | ANO9 | Anoctamin | ANOS1 | ANOS2P | ANP32A | ANP32A-IT1 | ANP32AP1 | ANP32B | ANP32C | ANP32D | ANP32E | ANPEP | ANTKMT | ANTXR1 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA10 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA2R | ANXA2R-AS1 | ANXA2R-OT1 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | ANXA8 | ANXA8L1 | ANXA8L2 | ANXA9 | AOAH | AOC1 | AOC2 | AOC3 | AOC4P | AOPEP | AOX1 | AOX2P | AP-1 Transcription Factor Complex | AP1AR | AP1B1 | AP1B1P1 | AP1G1 | AP1G2 | AP1M1 | AP1M2 | AP1S1 | AP1S2 | AP1S3 | AP2A1 | AP2A2 | AP2B1 | AP2M1 | AP2S1 | AP3B1 | AP3B2 | AP3D1 | AP3M1 | AP3M2 | AP3S1 | AP3S2 | AP4B1 | AP4B1-AS1 | AP4E1 | AP4M1 | AP4S1 | AP5B1 | AP5M1 | AP5S1 | AP5Z1 | APAF1 | APBA1 | APBA2 | APBA3 | APBB1 | APBB1IP | APBB2 | APBB3 | APC | APC2